[go: up one dir, main page]

WO2016090389A1 - Decongestant gum - Google Patents

Decongestant gum Download PDF

Info

Publication number
WO2016090389A1
WO2016090389A1 PCT/ZA2015/050028 ZA2015050028W WO2016090389A1 WO 2016090389 A1 WO2016090389 A1 WO 2016090389A1 ZA 2015050028 W ZA2015050028 W ZA 2015050028W WO 2016090389 A1 WO2016090389 A1 WO 2016090389A1
Authority
WO
WIPO (PCT)
Prior art keywords
gum
decongestant
chewing gum
dose
chewing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ZA2015/050028
Other languages
French (fr)
Inventor
Michael T. Rathogwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2016090389A1 publication Critical patent/WO2016090389A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/08Chewing gum characterised by the composition containing organic or inorganic compounds of the chewing gum base
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23GCOCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00Chewing gum
    • A23G4/06Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/12Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums

Definitions

  • This invention relates to a chewing gum to help middle ear air pressure equalisation.
  • the inventor is aware that during elevation changes or other ambient pressure changes the air pressure in the middle ear equalises with the ambient pressure via the Eustachian tube. Normally this happens intermittently by contraction of the tensor veli palatini muscles during swallowing, for example.
  • chewing gum which includes a gum base mixed with a decongestant.
  • the gum may include food safe flavouring and/ or food safe colouring.
  • the decongestant may be one or more of decongestants selected from an Alpha-adrenergic agonist and/ or a decongestant.
  • the Decongestant may be selected from pseudoephedrine, phenylephrine and/ or phenylpropanolamine.
  • the decongestants may be micro encapsulated to mask the bitter taste of pseudoephedrine, for example and to improve the organoleptic properties and compressibility.
  • the gum may also include naturally derived decongestants like menthol or eucalyptol.
  • the gum may also include a mucolytic agent such as acetylcysteine.
  • the gum may also include flavourings and/ or sugars or sweeteners.
  • the gum base may include polyols. Each dose of the gum may include between 10 and 60 mg of pseudoephedrine.
  • Each dose of the gum may include between 10 and 20 mg of phenylephrine.
  • Each dose of the gum may include between 25 and 75 mg of phenylpropanolamine.
  • One dose of the gum may include:
  • Another dose of the gum may include:
  • a further dose of the gum may include:
  • a first example of a dose of the gum includes:
  • a second example of a dose of the gum includes: 1610 mg of Health in Gum® (HIG) Gum base;
  • a third example of a dose of the gum includes:
  • the decongestant of the first example is replaced with oxymetazoline and menthol in 50:50 weight relationship.
  • any of the previous formulations include a pharmacologically active amount of Acrivastine or loratidine as an antihistamine.
  • any of the previous formulations also include a pharmacologically active amount of a mucolytic agent selected from acetylcysteine.
  • sweetener, non-stick agent and glidant is mixed to homogenous mixture and the decongestant is added and again mixed to form a homogenous mixture.
  • the gum base is then added and again mixed to homogenous mixture.
  • Flavourants may also be mixed in with the gum base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a chewing gum to provide relief to pressure related ear pressure ailments. The gum includes a gum base mixed with a decongestant.

Description

Title: Decongestant Gum
Technical field of the invention
This invention relates to a chewing gum to help middle ear air pressure equalisation.
Background to the invention
The inventor is aware that during elevation changes or other ambient pressure changes the air pressure in the middle ear equalises with the ambient pressure via the Eustachian tube. Normally this happens intermittently by contraction of the tensor veli palatini muscles during swallowing, for example.
Often, the process of equalisation of the air pressure in the middle ear is prevented or impeded, which can lead to minor to extreme discomfort and pain. Typically children and persons suffering from upper airway congestion may have trouble with the equalisation of air in the middle ear.
Persons can experience discomfort and pain during take-off and descents of aircraft, SCUBA diving, driving over a mountain, underground mining, hyperbaric chamber work and other situations with rapid changes in ambient pressure.
It is an object of the invention to provide an edible or chewable product to assist a person to equalise the air in their middle ear with ambient pressure.
General description of the invention
According to the invention there is provided chewing gum, which includes a gum base mixed with a decongestant.
The gum may include food safe flavouring and/ or food safe colouring. The decongestant may be one or more of decongestants selected from an Alpha-adrenergic agonist and/ or a decongestant.
The Decongestant may be selected from pseudoephedrine, phenylephrine and/ or phenylpropanolamine.
The decongestants may be micro encapsulated to mask the bitter taste of pseudoephedrine, for example and to improve the organoleptic properties and compressibility.
The gum may also include naturally derived decongestants like menthol or eucalyptol.
The gum may also include a mucolytic agent such as acetylcysteine.
The gum may also include flavourings and/ or sugars or sweeteners.
The gum base may include polyols. Each dose of the gum may include between 10 and 60 mg of pseudoephedrine.
Each dose of the gum may include between 10 and 20 mg of phenylephrine.
Each dose of the gum may include between 25 and 75 mg of phenylpropanolamine.
One dose of the gum may include:
between 138 and 316 mg of 19% potency Descote® pseudoephedrine
HCI; and
between 1546 and 1388 mg of Health in Gum® (HIG) Gum base. Another dose of the gum may include:
between 13 and 17 mg of phenylephrine; and
between 1550 and 1680 mg of Health in Gum® (HIG) Gum base.
A further dose of the gum may include:
25 and 75 mg of phenylpropanolamine; and
between 1550 and 1680 mg of Health in Gum® (HIG) Gum base. In use, a person will chew gum 30 minutes up to one hour before an expected pressure change and during the pressure change and the chewing of gum causes a person to produce saliva, which needs to be frequently swallowed, often unconsciously. The applicant believes that chewing a gum, in accordance with the invention, causes firstly frequent swallowing, secondly the release of a decongestant and/ or mucolytic over time and thirdly the release of the decongestant and/ or decongestant in close proximity to the Eustachian tube, which in combination chewing movements of the jaw provides a very effective means for a person to prepare the Eustachian tube for equalisation and to equalise pressure in the middle ear.
Detailed description of the invention
The invention is now described by way of examples. A first example of a dose of the gum includes:
157.9 mg of 19% potency Descote® pseudoephedrine HCI;
1546.1 mg of Health in Gum® (HIG) Gum base;
36 mg of powder flavour;
27 mg of magnesium stearate as non-stick agent;
18 mg of silicon dioxide as glidant;
1 1 mg liquid flavour; and
4 mg Stevia as sweetener.
A second example of a dose of the gum includes: 1610 mg of Health in Gum® (HIG) Gum base;
36 mg of powder flavour;
27 mg of magnesium stearate as non-stick agent;
18 mg of silicon dioxide as glidant;
1 1 mg liquid flavour; and
4 mg Stevia as sweetener.
A third example of a dose of the gum includes:
25 mg of phenylpropanolamine;
1610 mg of Health in Gum® (HIG) Gum base;
36 mg of powder flavour;
27 mg of magnesium stearate as non-stick agent;
18 mg of silicon dioxide as glidant;
1 1 mg liquid flavour; and
4 mg Stevia as sweetener.
In a fourth example, the decongestant of the first example is replaced with oxymetazoline and menthol in 50:50 weight relationship.
In a fifth example any of the previous formulations include a pharmacologically active amount of Acrivastine or loratidine as an antihistamine.
In a sixth example, any of the previous formulations also include a pharmacologically active amount of a mucolytic agent selected from acetylcysteine.
First the sweetener, non-stick agent and glidant is mixed to homogenous mixture and the decongestant is added and again mixed to form a homogenous mixture. The gum base is then added and again mixed to homogenous mixture. Flavourants may also be mixed in with the gum base.
It shall be understood that the examples are provided for illustrating the invention further and to assist a person skilled in the art with understanding the invention and are not meant to be construed as unduly limiting the reasonable scope of the invention.

Claims

1 . A chewing gum, which includes a gum base mixed with a decongestant.
2. A chewing gum as claimed in Claim 1 , wherein the decongestant is selected from an Alpha-adrenergic agonist and/ or a decongestant.
3. A chewing gum as claimed in Claim 1 , wherein the decongestant is selected from pseudoephedrine, phenylephrine and/ or phenylpropanolamine.
4. A chewing gum as claimed in any one of claims 1 to 3, wherein the decongestant is micro encapsulated.
5. A chewing gum as claimed in Claim 1 , wherein the decongestant is selected from naturally derived decongestant.
6. A chewing gum as claimed in any one of claims 1 to 4, which also includes a naturally derived decongestants.
7. A chewing gum as claimed in any one of claims 1 to 6, which also includes a mucolytic agent.
8. A chewing gum as claimed in any one of claims 1 to 7, wherein the gum base includes polyols.
9. A chewing gum as claimed in Claim 3, wherein each dose of the gum includes between 30 and 60 mg of pseudoephedrine.
10. A chewing gum as claimed in Claim 3, wherein each dose of the gum includes between 10 and 20 mg of phenylephrine.
1 1 . A chewing gum as claimed in Claim 3, wherein each dose of the gum may include between 25 and 75 mg of phenylpropanolamine.
PCT/ZA2015/050028 2014-12-01 2015-11-30 Decongestant gum Ceased WO2016090389A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201408788 2014-12-01
ZA2014/08788 2014-12-01

Publications (1)

Publication Number Publication Date
WO2016090389A1 true WO2016090389A1 (en) 2016-06-09

Family

ID=56092612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ZA2015/050028 Ceased WO2016090389A1 (en) 2014-12-01 2015-11-30 Decongestant gum

Country Status (2)

Country Link
WO (1) WO2016090389A1 (en)
ZA (1) ZA201508730B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639368A (en) * 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
EP0371584A2 (en) * 1988-10-28 1990-06-06 McNEIL-PPC, INC. Unpleasant taste masking compositions and methods for preparing same
WO2000056281A1 (en) * 1999-03-22 2000-09-28 Atp Avant-Garde Technologies & Product Marketing & Licensing S.A. Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained
US20060127473A1 (en) * 2004-12-13 2006-06-15 Nichols William M Compositions and methods for stabilizing active pharmaceutical ingredients
WO2006063189A2 (en) * 2004-12-10 2006-06-15 Novartis Ag Multi-layered chewing gum tablet with quick disintegration layer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639368A (en) * 1984-08-23 1987-01-27 Farmacon Research Corporation Chewing gum containing a medicament and taste maskers
EP0371584A2 (en) * 1988-10-28 1990-06-06 McNEIL-PPC, INC. Unpleasant taste masking compositions and methods for preparing same
WO2000056281A1 (en) * 1999-03-22 2000-09-28 Atp Avant-Garde Technologies & Product Marketing & Licensing S.A. Composition for medicated chewing gums, process for manufacturing the same and tablets so obtained
WO2006063189A2 (en) * 2004-12-10 2006-06-15 Novartis Ag Multi-layered chewing gum tablet with quick disintegration layer
US20060127473A1 (en) * 2004-12-13 2006-06-15 Nichols William M Compositions and methods for stabilizing active pharmaceutical ingredients

Also Published As

Publication number Publication date
ZA201508730B (en) 2017-03-29

Similar Documents

Publication Publication Date Title
MX2022005285A (en) Oral product and method of manufacture.
MY209708A (en) Niraparib formulations
NZ626672A (en) Solid nicotine-comprising dosage form with reduced organoleptic disturbance
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
WO2007076025A3 (en) Compositions providing a sensation substantially similar to that provided by menthol
EP3003384B1 (en) Oral solution comprising atomoxetine hydrochloride
MY145790A (en) Composition
BR0308927A (en) Pleasant Chewable Tablet
CN106102477B (en) Compositions with reduced bitter taste perception
MX2022004738A (en) Superfine compounds and production thereof.
RU2011107834A (en) CONFECTIONERY PRODUCT, CHEWING RUBBER AND METHOD FOR MAINTAINING MOISTURIZING MOISTURIZATION IN THE ORAL CAVITY
MY206893A (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2015192015A3 (en) Sweet taste receptor antagonist compositions
WO2016090389A1 (en) Decongestant gum
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CN107510671A (en) A kind of multi-functional auxiliary material composition of oral dosage form and the preparation of oral dosage form
IL273240A (en) Oral-surface administered preparation for the prevention of illnesses acquired via the oral cavity and the pharynx
BRPI0715756B8 (en) pharmaceutical composition for oral administration, its uses, and medicine
Frossard et al. A40 A HARD DAY'S NIGHT: DRUG INDUCED LUNG DISEASE: Acute Uvulitis Secondary To Electronic Cigarette Use
JP2017052778A5 (en)
WO2020076257A3 (en) A healthy soft jelly candy formulation and its production method
JP5918584B2 (en) Taste masking method
NO20064963L (en) Composition with improved palatability, silt freeze-dried particles, free-flowing compressible powder-like freeze-dried particles, process for making the same, pharmaceutical compositions with improved palatability, etc.
KR102329377B1 (en) solid formulation
NO20065627L (en) Oral products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15865531

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15865531

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13.07.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 15865531

Country of ref document: EP

Kind code of ref document: A1